Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
about
Molecular topology as novel strategy for discovery of drugs with aβ lowering and anti-aggregation dual activities for Alzheimer's diseaseEfficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small moleculeImmunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse modelMetals and amyloid-beta in Alzheimer's diseaseLipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in miceProtein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseasesTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsRole of methylglyoxal in Alzheimer's diseaseNF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 productionCompounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeuticsAggresome formation and neurodegenerative diseases: therapeutic implicationsAbeta mediated diminution of MTT reduction--an artefact of single cell culture?Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screeningVirtual and In Vitro Screens Reveal a Potential Pharmacophore that Avoids the Fibrillization of Aβ1-42Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodentOrientation of tyrosine side chain in neurotoxic Aβ differs in two different secondary structures of the peptideInhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption.Aberrant protein structure and diseases of the brain.Growth factors in synaptic function.Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein.At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillationEfavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice.Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Abeta oligomer-induced cytotoxicity.Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils.Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agentsUpregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Abeta42 reduces their differentiation potential.New Alzheimer amyloid beta responsive genes identified in human neuroblastoma cells by hierarchical clustering.Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivoOxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.Quantifying prefibrillar amyloids in vitro by using a "thioflavin-like" spectroscopic method.Can peripheral leukocytes be used as Alzheimer's disease biomarkers?Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disordersAlzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque depositionAPP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesisTransgenic Drosophila models of Alzheimer's disease and tauopathiesAn update on the amyloid hypothesis.Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticityGenetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease
P2860
Q21132276-BC4C3765-4367-4380-AF96-4BCC9AB63832Q24563817-B1F200D4-F5B3-485A-8FBE-BF962DB92EDDQ24608911-F7A93E94-A05F-44E7-A780-2FECC3AED082Q24643555-376AC6EC-CE03-49F1-A61C-8A065EC16F40Q24649564-8CA3F515-4A28-4FB6-A733-4EBA2974FD59Q24650014-17B99C2F-A820-4457-A525-07DD2FEC3BA8Q26822002-21EC42AA-476C-4DB7-961C-8708E28772BDQ27004644-83291A98-4241-4D8A-AD5D-C0EB7C49F61BQ28196676-0C35D8FB-DCD7-468A-8325-BAA51B65DDFFQ28237347-8F53C314-1C39-4E20-8B59-EED1895292BAQ28265926-A21C0926-BACB-4E70-92C7-ABC02CD6FF54Q28473625-99193931-397B-4553-8FBE-641B1C0E4FA3Q28475342-A6CB37B4-7FC7-45F4-98C6-CCC89ACF291AQ28546473-0020312E-0E94-47A3-AE01-C9D21D11181AQ28578059-18646E9E-61CA-44C1-9FCF-A90F432466D3Q28596366-44EEB398-A014-4237-8CF5-8B4D6CC2D22BQ30175697-C4E2D56F-0033-49A7-8507-1DA9E0E7EB08Q30395060-49FF8DDA-2483-4F11-8DAE-3713751BFFFCQ30449007-F54AB045-1173-4747-94BD-9B0B9184C0CDQ30481489-FEB36FA2-6644-4DB6-9E6E-5DC6B6BF4C34Q30481562-565CD52C-D7D5-408E-A578-2F6BCE86BDAFQ31159582-8D2FED0F-836F-4334-914C-1DDDF68806FCQ33263907-75E3A49A-F09B-4270-86E1-35974171CB22Q33266053-E0B76809-7011-4245-BE53-FF27B5F1875AQ33302932-D9446F97-0C1F-464C-8258-8C68FFFDEC1BQ33366459-D205AFF6-76D6-483F-A121-AD0A53F45BD7Q33385904-0C07CF95-16C2-4A67-A183-C8BF273321F9Q33393396-8109B7F2-3F38-45B0-B327-8FFC74B12E5AQ33496736-85DC3B44-308F-44FB-93A7-97DAD6DB56BBQ33592247-6477F83C-F67C-4133-9761-90090183FC8EQ33639885-D826EE35-92CD-4E01-991B-31F19D41E65DQ33647141-3D2FFCA9-D1A5-4796-AE82-5AF88AE96118Q33689076-7600FE72-E344-41CA-8EDD-D1EBF1C7982AQ33716773-36AD8B12-B760-4192-BD72-57FFB73F0F71Q33756388-AE2B3E01-8A2C-48FA-B69F-6C67B20F295EQ33759956-C9FC6F74-4E17-40C8-82C1-C2F56C804A65Q33770749-EF912D76-6C98-4567-8DB3-C16B811944BEQ33800962-374F76E8-6971-46DE-B827-8AC7DBF6183AQ33805904-B9F4C952-E8C2-41ED-8C8F-ACA50585BB5DQ33847567-D27DCD6B-84BA-4BD9-BD87-39E91320F75C
P2860
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@ast
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@en
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@nl
type
label
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@ast
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@en
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@nl
prefLabel
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@ast
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@en
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@nl
P2093
P356
P1476
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition.
@en
P2093
P304
P356
10.1042/BST0300552
P577
2002-08-01T00:00:00Z